Natera, Inc. (NASDAQ:NTRA) CEO Sells $4,053,750.00 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 37,500 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $108.10, for a total transaction of $4,053,750.00. Following the transaction, the chief executive officer now owns 213,351 shares in the company, valued at approximately $23,063,243.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, June 17th, Steven Leonard Chapman sold 6,105 shares of Natera stock. The stock was sold at an average price of $111.61, for a total transaction of $681,379.05.
• On Wednesday, May 15th, Steven Leonard Chapman sold 6,779 shares of Natera stock. The stock was sold at an average price of $107.08, for a total transaction of $725,895.32.
• On Monday, April 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $93.14, for a total transaction of $380,383.76.
• On Tuesday, April 23rd, Steven Leonard Chapman sold 2,552 shares of Natera stock. The stock was sold at an average price of $91.38, for a total transaction of $233,201.76.
• On Monday, April 15th, Steven Leonard Chapman sold 6,816 shares of Natera stock. The shares were sold at an average price of $93.13, for a total value of $634,774.08.

Natera Price Performance

NTRA stock opened at $111.64 on Thursday. The company has a market capitalization of $13.71 billion, a P/E ratio of -35.78 and a beta of 1.48. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $117.23. The business has a 50 day simple moving average of $105.70 and a 200-day simple moving average of $86.87. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.16. The business had revenue of $367.70 million during the quarter, compared to the consensus estimate of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The company’s revenue was up 52.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.23) earnings per share. As a group, equities analysts anticipate that Natera, Inc. will post -2.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Craig Hallum assumed coverage on Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. Robert W. Baird raised their price objective on Natera from $99.00 to $117.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Jefferies Financial Group started coverage on Natera in a research note on Monday, June 3rd. They issued a “buy” rating and a $142.00 target price for the company. BTIG Research raised their price objective on Natera from $100.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Finally, TD Cowen raised their price objective on Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a research report on Friday, May 10th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $101.19.

Institutional Investors Weigh In On Natera

Several large investors have recently modified their holdings of NTRA. Norges Bank purchased a new stake in shares of Natera during the fourth quarter worth approximately $83,970,000. American Century Companies Inc. raised its stake in shares of Natera by 115.7% during the third quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company’s stock worth $73,203,000 after purchasing an additional 887,409 shares during the last quarter. Perceptive Advisors LLC raised its stake in shares of Natera by 289.7% during the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after purchasing an additional 632,047 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Natera by 5.7% during the fourth quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after purchasing an additional 588,147 shares during the last quarter. Finally, First Light Asset Management LLC raised its position in Natera by 295.9% in the first quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock worth $60,063,000 after acquiring an additional 490,822 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.